Fecal Transplantation for the Treatment of Clostridium difficile Infection.
About OpenBiome OpenBiome is the first public stool bank, founded to expand safe access to
fecal transplantation for patients with recurrent C. difficile infection and to catalyze research on the microbiome's role in human health.
«Through it, we will provide safe access to
fecal transplantation for patients with recurrent C. difficile today, and help Finch pursue FDA approval so that patients have this access in perpetuity.
OpenBiome was founded to expand safe access to
fecal transplantation for patients with recurrent C. difficile infection and to catalyze research on the role of the microbiome in human health.
Not exact matches
Fecal microbial
transplantation (FMT) has gained acceptance
for treating Clostridium difficile infection, a life threatening and difficult to treat dysbiosis that often is caused by heavy use of antibiotics.
«So far, it has not been sufficiently tested whether and how successful
fecal transplantation is
for the permanent settlement of microbiota from a healthy donor to a patient,» said Alexander Loy of the Department of Microbiology and Ecosystem Research, University of Vienna.
«Meta studies have shown that the controlled grafting of
fecal transplantation from healthy donors is a safe and very effective treatment of acute diarrheal diseases caused by the pathogenic bacterium Clostridium difficile,» said Sieglinde Angelberger, gastroenterologist at the University Clinic
for Internal Medicine III of the Medical University of Vienna and author of the study: «this was the reason why we applied this therapy
for the treatment of patients with chronic intestinal diseases.»
Fecal microbiome transplantation (FMT) via oral fecal microbial capsules for recurrent Clostridium difficile infections (r
Fecal microbiome
transplantation (FMT) via oral
fecal microbial capsules for recurrent Clostridium difficile infections (r
fecal microbial capsules
for recurrent Clostridium difficile infections (rCDI).
«
Fecal microbiota
transplantation has been very successful
for many patients with C. difficile infections, but we've never known why.
In a retrospective, multicenter, longitudinal observational study, the response rates to
fecal microbiota
transplantation as a treatment
for recurrent C. difficile infection were determined a 30 and 90 days, and adverse events were registered.
The authors call
for more uniform documentation of the clinical efficacy and safety of
fecal microbiota
transplantation.
Analysis of Treatment Outcomes
for Recurrent Clostridium difficile Infections and
Fecal Microbiota
Transplantation in a Pediatric Hospital
For patients who fail multiple courses of antibiotic treatment,
fecal transplantation has been shown to prevent recurrence in more than 85 % of cases.
Fecal Microbiota
Transplantation in Inflammatory Bowel Disease - a Primer
for the Internists — Gaurav Syal — The American Journal of Medicine
Analysis of Treatment Outcomes
for Recurrent Clostridium difficile Infections and
Fecal Microbiota
Transplantation in a Pediatric Hospital — Aileen Aldrich — The Pediatric Infectious Disease Journal
Oral, capsulized, frozen
fecal microbiota
transplantation for relapsing Clostridium difficile infection.
Probiotics / prebiotics / antibiotics Tacrolimus concentration to dose ratio in solid organ transplant patients treated with
fecal microbiota
transplantation for recurrent Clostridium difficile infection.
For this subgroup of patients, a promising new treatment called
Fecal Microbiota
Transplantation (FMT) brings hope.
The first study of the social and ethical issues associated with a provocative approach to treatment
for ulcerative colitis has found that the majority of potential patients are eager
for what is now called «
fecal microbiota
transplantation» to become available, although many have concerns about donor selection, screening, and methods of delivery.
June 2, 2011 Patients with bowel disease eager to test «
fecal» therapy The first study of the social and ethical issues associated with a provocative approach to treatment
for ulcerative colitis has found that the majority of potential patients are eager
for what is now called «
fecal microbiota
transplantation» to become available, although many have concerns about donor selection, screening, and methods of delivery.
This study provides hope
for a cure
for Crohn's by manipulating the microbiome through diet and supplementation, even
fecal transplantation.»
Our
Fecal Microbiota Transplantation (FMT) residential programs include fecal transplants for the treatment of Clostridium Difficile infection (C.Diff) and a comprehensive educational program for many other conditions including obesity, Crohn's disease, ulcerative colitis, anxiety, depression and schizophr
Fecal Microbiota
Transplantation (FMT) residential programs include
fecal transplants for the treatment of Clostridium Difficile infection (C.Diff) and a comprehensive educational program for many other conditions including obesity, Crohn's disease, ulcerative colitis, anxiety, depression and schizophr
fecal transplants
for the treatment of Clostridium Difficile infection (C.Diff) and a comprehensive educational program
for many other conditions including obesity, Crohn's disease, ulcerative colitis, anxiety, depression and schizophrenia.
The 5 - day program
for Fecal Microbiota
Transplantation (FMT) includes two colonics, three infusions (transplants) of a fresh specimen and a chamomile enema.